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Owing to recent advances in diagnostic and surgical techniques for cancer, a patient diagnosed with two or more
neoplasms is not rare. We report on the case of a 58-year-old male with multiple primary malignant neoplasms,
who suffered from three histological types of malignant neoplasm in six organs, namely the glottis, renal pelvis,
urinary bladder, oral floor, prostate, and esophagus in chronological order. The first neoplasm was a squamous cell
carcinoma of the glottis diagnosed in 2006. The second and third neoplasms were urothelial carcinomas of the right
renal pelvis and urinary bladder, respectively, diagnosed in 2008. The remaining three neoplasms were diagnosed in
2010, namely a squamous cell carcinoma of the oral floor, an adenocarcinoma of the prostate, and a squamous
cell carcinoma of the esophagus. The glottic cancer and esophageal cancer were treated by external radiation
therapy. The malignant neoplasms of the oral floor and those which originated in the urinary tract were surgically
resected. All neoplasms except the malignant neoplasm of the oral floor were well controlled. The patient died of
cervical lymph node metastasis from the squamous cell carcinoma of the oral floor in January 2011. As far as we
know, the present report is the first one on this combination of primary malignant neoplasms.
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Early detection and development of novel treatment mo-
dalities are improving longevity of patients with cancer.
Consequently, the increasing possibility of suffering from
multiple primary malignant neoplasms (MPMN) is
emerging as a common problem for cancer survivors;
MPMN were first described by Billroth et al. [1]. In
1932, Warren and Gates proposed three criteria for the
diagnosis of a second primary cancer: i) each tumor
must present a definite clinical and histological picture
of malignancy; ii) each tumor must be histologically dis-
tinct; and iii) the probability that one was a metastatic* Correspondence: uromotofumi@gmail.com
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article, unless otherwise stated.lesion from the other must be excluded [2]. Moertel
proposed new definition of MPMN, where synchronous
malignancies are those that occur within 6 months of
the diagnosis of a previous malignant neoplasm and meta-
chronous ones are those that occur more than 6 months
apart [3]. According to the Surveillance, Epidemiology,
and End Results (SEER) Program Coding and Staging
Manual 2004, synchronous tumors are multiple tumors
diagnosed within 2 months of the original/initial diagno-
sis, and metachronous ones are multiple tumors or lesions
that occur more than 2 months after the original/initial
diagnosis [4].
In this report, we describe the rare case of a patient
who suffered from three histological types of malignant
neoplasm in six organs, namely a squamous cell carcin-
oma (SCC) of the glottis, oral floor, and esophagus, atral Ltd. This is an Open Access article distributed under the terms of the
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urinary bladder, and an adenocarcinoma (AC) of the
prostate.
Case presentation
A 58-year-old male, a manager of a tavern, habitual
drinker (one bottle of beer a day for 36 years), and heavy
smoker (20 cigarettes a day for 33 years), was referred to
our department for asymptomatic gross hematuria on
February 2008. Two years before, he had been diagnosed
with a SCC of the glottis, pT1N0M0 (stage I) which was
treated by 70 Gy of external radiation therapy at the
University of Tokyo Hospital. Since November 2007, he
had been diagnosed with alcoholic liver cirrhosis and
had received conservative medical treatment at a nearby
hospital. He did not have any family history of malignant
neoplasms. An abdominal computed tomography (CT)
showed right hydronephrosis and tumor of the right
renal pelvis. A retrograde pyelography also supported
the findings of the abdominal CT. We conducted cystos-
copy prior to the surgery; however, no distinct bladder
tumors could be seen. We diagnosed him with right
renal pelvic tumor and performed right nephroureterect-
omy on April 2008. The pathological diagnosis was UC of
the right renal pelvis, high-grade, pT3N0M0 (stage III)
including carcinoma in situ in the renal pelvis. Adjuvant
chemotherapy was not administered due to chronic liver
dysfunction and thrombocytopenia. Except for alcoholic
liver cirrhosis, no other medical conditions or treatment-
induced immunosuppression were recorded. After the
surgery, follow-up was conducted by a cystoscopy every
3 months and an abdominal CT scan every 6 months.
In September 2008, cystoscopy revealed multiple bladder
tumors. He underwent transurethral resection of bladder
tumor (TURBT) in October 2008. The pathological finding
was UC of the urinary bladder, high-grade, pTisN0M0
(stage 0is). He received weekly intravesical instillation
of bovine Bacille-Calmette Guérin (Connaught strain,
81 mg/once a week) for 8 weeks to prevent recurrence
of the bladder tumor.
In October 2009, he underwent TURBT again for re-
current bladder cancer. The pathological finding was UC
of the urinary bladder, high-grade, pTis. UC was also
found at the prostatic urethra, high-grade, pTis. We rec-
ommended a radical cystectomy and urethrectomy with
urinary diversion. On December 2009, he became aware
of a mass beneath his tongue. We found a papillary
superficial tumor on the left side of the oral floor. Upon
consultation with the department of oral surgery, the
tumor was resected in January 2010. The pathological
finding was a well differentiated SCC of the oral floor,
pT1N0M0 (stage I). Just 2 weeks after the oral surgery,
we performed radical cystectomy and urethrectomy with
an ileal conduit urinary diversion. The pathological findingswere UC in situ involving the urethra and prostatic duct,
high-grade, pTisN0M0 (stage 0is) and incidental AC of the
prostate, Gleason score 3 + 3, pT1aN0M0 (stage IIa).
In March 2010, 6 weeks after resection of the tumor
of the oral floor, a head and neck CT scan suggested a
submental lymph node swelling. He underwent bilateral
cervical lymphadenectomy and 17 lymph nodes were
resected. As a result, only one submental lymph node
was diagnosed as a metastasis of well differentiated SCC
of the oral floor. On June 2010, he experienced dysphagia.
During an upper gastrointestinal endoscopy, biopsies for
erosive lesions at the upper and middle portions of the
esophageal mucosa were performed. The pathological
finding was a well differentiated SCC of the esophagus,
pT1N0M0 (stage I) and external radiation therapy with
total 68.4 Gy was performed. From July 2010 onwards,
cervical lymph node metastasis grew rapidly and gradually
caused a tracheal obstruction. He underwent tracheotomy
on November 2010. After receiving palliative care, he died
of cancer cachexia on January 2011. An autopsy was not
performed.
The malignant neoplasms in six organs are listed se-
quentially in Table 1. Figure 1 shows hematoxylin-eosin
staining and immunohistochemical staining using anti-
p53 antibody of SCC and UC. It is reported that nuclear
immunoreactivity of p53 is a good surrogate of TP53
mutations [5]. Immunoreactivity of p53 in tumor cells
was different among SCCs; the glottic cancer and
esophageal cancer in the upper portion were diffusely
positive, while the oral cancer, esophageal cancer in the
middle portion, and cervical lymph node metastasis of
the oral cancer were completely negative. As for the
renal pelvic cancer and bladder cancer, immunoreactivity
of p53 was weakly positive in scattered cancer cells.
Discussion
The actual risk of developing MPMN in Japan is un-
known since cancer registration systems have yet to be
legislated in Japan. Demandante et al. reviewed the lit-
erature published from 1966 to 2000 and reported that
the prevalence of MPMN varied from 0.734% to 11.7%
[8]. Based on epidemiological data from the National
Cancer Institute’s SEER Program in 2003, it is estimated
that approximately 16% of new cancers reported to their
registry represent a second- or high-order malignancy
[9]. The Osaka Cancer Registry, one of the regional can-
cer registration systems in Japan, has been operating
since December 1962 and has accumulated about one
million cancer incidence data in Osaka prefecture [10].
Using the Osaka Cancer Registry data, Tabuchi et al. re-
ported that 10-year cumulative risk of metachronous
second primary cancer in Japanese male patients was
10.2% at 50 to 59 years of age, 16.2% at 60 to 69 years of
age, and 21.8% at 70 to 79 years of age [11].
Table 1 List of three histological types of malignant neoplasm in six organs







April/2006 Glottis SCC Diffusely positive C320 8071/31 pT1
April/2008 Renal pelvis UC Weakly positive C659 8120/33 pT3
October/2008 Urinary bladder UC Weakly positive C675 8120/32 pTa
C676 8120/23 pTis
January/2010 Oral floor SCC Completely negative C041 8071/31 pT1
January/2010 Prostate AC Not examined C619 8140/32 pT1a
June/2010 Esophagus C154 8070/31 pT1
Upper: 22 cm from incisor SCC Diffusely positive
Middle: 30 cm from incisor SCC Completely negative
We classified malignant neoplasms by the International Classification of Diseases for Oncology version 3 (ICD-O-3) [6]. The T-stage was based on the Union for
International Cancer Control TNM classification of malignant tumors (7th Edition) [7].
SCC, Squamous cell carcinoma; UC, Urothelial carcinoma; AC, Adenocarcinoma.
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the number of malignant neoplasms and their combin-
ation. We could not find out any case reports of the
same combination of neoplasms on either the PubMed
or the Japan Medical Abstracts Society databases. It is
difficult to estimate the risk of quintuple cancers; how-
ever, Rabbani et al. estimated the risk of MPMN in pa-
tients with renal cell carcinoma [12]. Of 551 patients,
they reported that the incidence of double cancer was
26.9%, triple cancer was 6.2%, quadruple cancer was
1.1%, and quintuple cancer was 0.2% [12]. Liu et al. stud-
ied the types of second primary malignancies among the
patients with head and neck cancer [13]. The types of
second primary malignancy with adjusted hazard ratio
(95% confidence interval) were esophageal cancer 3.47
(2.40 to 5.03), prostate cancer 0.94 (0.45 to 1.95), bladder
cancer 0.90 (0.39 to 2.10), among others [13]. Powell
et al. considered the prognosis of patients with MPMN
[14] by dividing patients with MPMN into synchronous
and metachronous cases according to the classification
proposed by Moertel [3]. Overall survival ratio was sig-
nificantly lower in the patients with synchronous
MPMN than those with metachronous MPMN (adjusted
hazard ratio 0.50, P <0.001).
Regarding the etiology of multiple primary malignan-
cies, several factors have been incriminated such as genetic,
hormonal (e.g., sex steroid), iatrogenic (e.g., chemotherapy,
radiation therapy, hormonal and immunosuppressive medi-
cations), and immunologic factors [15,16]. In particular,
tobacco smoking causes cancers of the lung, oral cavity,
naso-, oro-, and hypopharynx, nasal cavity and accessory
sinuses, larynx, esophagus, stomach, pancreas, colorec-
tum, liver, kidney (body and pelvis), ureter, urinary blad-
der, uterine cervix and ovary (mucinous), and myeloid
leukemia [17]. In the present case, alcoholic liver cirrhosis,
tobacco smoking, and external radiation therapy forglottic cancer may have played a role in MPMN develop-
ment. Several investigators have observed that patients
with cancers of these sites developed a second primary
cancer within the same anatomic region [18-20]. Wynder
et al. publicized that continuation of smoking habit after
diagnosis of the index cancer increased the risk for devel-
opment of a second primary lesion [21]. Heavy alcohol
consumption also predisposes certain sites to tumorigen-
esis, but primarily in conjunction with tobacco usage. In
spite of cessation of smoking and drinking habits after the
diagnosis of the glottic cancer, our patient developed
MPMN.
Hereditary forms of adult cancers are also frequently
associated with multiple primary cancers [22,23]. If the
nature of the hereditary predisposition is similar to that
of childhood cancers, i.e., an inherited mutation that re-
duces the subsequent number of mutations necessary in
each cell of the target organ, then such individuals may
have a high rate of spontaneous tumors and a unique
sensitivity to environmental agents [24]. Kotnis et al.
conducted a case control study to assess genetic predis-
position in a biologically-enriched clinical model system
of tobacco-related cancers occurring as MPMN. They
found that tobacco habit and three genetic polymor-
phisms, including Tp53 (Arg72Arg), XRCC1 (Arg399His),
and meH (Tyr113His), formed the best model for develop-
ing tobacco-associated MPMN [25].
In 1953, Slaghter et al. proposed field cancerization, a
process whereby the epithelial lining has been continu-
ously exposed to tobacco and/or alcohol, leading to ex-
tensive premalignant and malignant cytologic changes
and an increased risk for multiple independent tumor
development [26]. Field cancerization in the epithelium
has become accepted as playing a role in the develop-
ment of MPMN in the same system; however, molecular







Figure 1 The expression of p53 in SCC and UC. Tissue samples were stained by hematoxylin-eosin (left column) and anti-p53 antibody diluted
1:50 (Clone DO-7, Leica Biosystems, Wetzlar, Germany; right column). Immunoreactivity of p53 in tumor cells was identified by nuclear brown
color. (A and a) Glottic cancer; (B and b) Oral cancer; (C and c) Esophageal cancer (upper portion); (D and d) Esophageal cancer (middle
portion); (E and e) Renal pelvic cancer; (F and f) Bladder cancer. Scale bars, 100 μm.
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of second primary head and neck SCC is clonally related
to an index tumor, despite the presence of intervening
normal mucosa and significant separation by normal mu-
cosa. The same types of carcinogens and oncogenes seem
to be responsible for the development of neoplasms in
cases of other associations such as breast and endomet-
rial/ovarian tumors [28-31].
In the present case, immunoreactivity of p53 in tumor
cells was different among SCCs, suggesting that these
cancers were polyclonal, although distinct genetic abnor-
malities including loss of heterogeneity, gene mutations,
and influence of oncogenic viral infection may be neces-
sary to definitely determine polyclonality.
Another point of interest may be the origin of UC of
the renal pelvis and urinary bladder. According to the
report from the International Agency for Research on
Cancer [32], high-grade UC is likely to have high level
amplifications and TP53 mutations. In the present pa-
tient, however, immunoreactivity of p53 in the both
high-grade UCs was very weak. The atypical finding
ironically suggests UC of the renal pelvis and urinary
bladder might be of monoclonal origin.
Modern molecular biologic techniques might help in
the understanding of the biology involved and in design-
ing effective diagnostic and therapeutic strategies to deal
with these tumors.
Conclusions
A rare case of MPMN of three histological types of malig-
nant neoplasm in six organs was reported. Epidemiological
and clinicopathological studies of MPMN are crucial
for early detection and proper intervention of high risk
patients.
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